Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Net Margin: 2022-2025

Historic Net Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Sep 2025 value amounting to 7.47%.

  • Arcutis Biotherapeutics' Net Margin rose 10028.00% to 7.47% in Q3 2025 from the same period last year, while for Sep 2025 it was -13.94%, marking a year-over-year increase of 12703.00%. This contributed to the annual value of -71.25% for FY2024, which is 36854.00% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Net Margin is 7.47%, which was up 138.32% from -19.49% recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Net Margin ranged from a high of 3,507.40% in Q1 2022 and a low of -14,856.41% during Q3 2022.
  • Over the past 3 years, Arcutis Biotherapeutics' median Net Margin value was -92.81% (recorded in 2024), while the average stood at -480.58%.
  • Examining YoY changes over the last 5 years, Arcutis Biotherapeutics' Net Margin showed a top increase of 1,470,720bps in 2023 and a maximum decrease of 638,766bps in 2023.
  • Quarterly analysis of 4 years shows Arcutis Biotherapeutics' Net Margin stood at -2,432.25% in 2022, then spiked by 194,220bps to -490.05% in 2023, then skyrocketed by 47,493bps to -15.12% in 2024, then spiked by 10,028bps to 7.47% in 2025.
  • Its last three reported values are 7.47% in Q3 2025, -19.49% for Q2 2025, and -38.06% during Q1 2025.